#High Street Pharma

[healthyfy4me]

HighStreetPharma Review (2023) - Is High Street Pharma legit?

To learn if HighStreetPharma is truly the best modafinil provider, delivering the most affordable prices, the best product, and assured worldwide delivery, read the review. Imagine not having to spend hours waiting in line at the pharmacy or dealing with the complicated and often expensive process of obtaining prescription medications. Well, there’s good news! HighStreetPharma is a one-stop-shop for all your prescription pharmaceutical needs. However, with so many online pharmacies out there, it can be tough to determine if HighStreetPharma is the best choice for you. 

[patrickferrero1991]

HighStreetPharma Reviews | Vendor Reality check

[healthbuddy4]

Title: HighStreetPharma Review (2023)  -  Is High Street Pharma legit?

To learn if HighStreetPharma is truly the best modafinil provider, delivering the most affordable prices, the best product, and assured worldwide delivery, read the review.

Add Alt tag in the Image: alt=”HighStreetPharma”

Imagine not having to spend hours waiting in line at the pharmacy or dealing with the complicated and often expensive process of obtaining prescription medications.

Well, there's good news! HighStreetPharma is a one-stop-shop for all your prescription pharmaceutical needs. However, with so many online pharmacies out there, it can be tough to determine if HighStreetPharma is the best choice for you.

That's where we come in. In this review, we'll take a closer look at HighStreetPharma to help you make an informed decision. We'll cover everything from their background and reputation to their product line and customer support.

Whether you're a busy student striving for academic excellence or a working professional looking to boost productivity, HighStreetPharma could be the answer to your prayers.

But let's be real - not all online pharmacies are created equal, and the internet can be a risky place. Therefore, it's crucial to make sure that the company you're dealing with is trustworthy and legitimate.

We understand the importance of making informed decisions when it comes to your health and wellbeing, so we've taken the time to research HighStreetPharma thoroughly. So sit back, relax, and read on to discover everything you need to know about HighStreetPharma.

The Risks of Buying Medication Online From Highstreetpharma

Although ordering prescription drugs online can be convenient, it's vital to understand the hazards. Although HighStreetPharma is a trustworthy online pharmacy, it's important to think about any potential risks associated with ordering prescription drugs online.

People can now more easily get prescription prescriptions from the convenience of their own homes thanks to the internet. But there is a risk associated with this convenience. The likelihood of acquiring fraudulent or counterfeit goods is one of the biggest risks connected to online drug purchases. 

Since consumers frequently find it challenging to tell the difference between counterfeit and genuine pharmaceuticals, they can be very harmful. It might be difficult to guarantee that the products being offered online are authentic and safe without appropriate regulation and control. 

Because of this, it's crucial to only purchase medicines from reputable vendors who have a track record of offering genuine, high-quality goods. HighStreetPharma makes every effort to ensure that its goods adhere to the highest standards of quality since it is dedicated to giving its customers real pharmaceuticals that are secure and efficient.

The potential for customs problems while purchasing medication online is another concern, particularly if you reside in a nation with stringent import laws. Certain prescriptions could not be allowed into certain nations, and if customs seizes your box, you might be charged fees or face other legal repercussions. (Source) 

History of High Street Pharma

The healthcare sector is not an exception to the way the internet has altered how we make purchases. HighStreetPharma has quickly established a reputation for itself by offering cost-effective and dependable items in response to the growing demand for prescription pharmaceuticals online.

HighStreetPharma was founded in 2019. The pharmacy provides a wide range of prescription drugs, including Modafinil, which is well-known for its benefits to cognitive function.

The dedication of HighStreetPharma to client happiness is unparalleled. Customers may quickly traverse the company's website and find the products they require thanks to the user-friendly online platform it provides. 

At HighStreetPharma, privacy and confidentiality are also important priorities. The pharmacy takes all necessary precautions to keep customer and financial information private. 

Why Choose HighStreetPharma to Buy Modafinil Online?

The dedication of HighStreetPharma to offering top-notch items is one of their most important advantages. They assert that they obtain their medication from authorized producers and wholesalers, guaranteeing the best possible quality for their goods. This is crucial when it comes to modafinil because it is a strong medication that needs to be handled and stored carefully.

The reasonable pricing at HighStreetPharma makes it a great choice for anyone looking to purchase modafinil online. Compared to other online pharmacies, they provide affordable costs for their modafinil goods. 

Additionally, HighStreetPharma provides shipping to most countries of the world. They offer consumers tracking information and delivery to the majority of nations worldwide. Customers may check the progress of their package and make sure that it arrives securely, which can increase their sense of security when obtaining a prescription online.

Last but not least, HighStreetPharma has a helpful customer care team that can help with any questions or problems clients may have. This might be especially useful for those who are unfamiliar with ordering prescription drugs online and may have queries or worries regarding the procedure. Customers can receive assistance from the customer support team regarding ordering, shipping, and payment methods, offering a simple and hassle-free experience.

Overall, HighStreetPharma is a trustworthy alternative for people wishing to order  modafinil online thanks to their dedication to high-quality products, reasonable costs, global shipping, and attentive customer support.

Is HighStreetPharma Legit?

The healthcare sector is one that demands the highest level of trust and faith. Customers must take additional care while choosing the correct online pharmacy when ordering prescription medications online. Finding a trustworthy source for prescription drugs has grown to be very difficult due to the rise in fake goods and unscrupulous websites.

HighStreetPharma is a licensed online pharmacy that complies fully with all the rules and guidelines established by the Indian government. The company's drive to offer clients trustworthy products is demonstrated by its commitment to moral and ethical business practices. Every prescription drug sold by HighStreetPharma is obtained from reliable, licensed producers

Numerous client testimonials that praise the company's quick and dependable shipping, attentive customer service, and premium items prove the excellent caliber of the products offered by HighStreetPharma. 

In short, HighStreetPharma is a good option to buy from if you're looking to buy Modafinil or any other prescription drug. HighStreetPharma is unquestionably the real deal thanks to its dedication to moral business conduct, first-rate customer service, and high-quality products.

Product Offerings

HighStreetPharma is the ideal online location for anyone wishing to enhance their cognitive performance when it comes to Modafinil. Among the top Modafinil brands offered on the website are Modalert, Modvigil, and Waklert. 

Due to their well-known capacity to improve focus, attention, and alertness, these products are well-liked by both professionals and business owners as well as students. 

The online pharmacy HighStreetPharma offers a wide variety of additional prescription drugs as well, such as treatments for anxiety, hair loss, and erectile dysfunction. 

HighStreetPharma is a one-stop shop for all of your prescription drug needs thanks to its wide selection of goods. HighStreetPharma has you covered whether you want to enhance your cognitive function, treat a medical condition, or simply maintain your health and well-being. 

HighStreetPharma is a dependable and trustworthy online pharmacy with a focus on quality, price, and customer pleasure.

Customer Reviews

It's crucial to pick a reputable and trustworthy vendor while purchasing medications online. One such vendor is HighStreetPharma, which has a 4.6 out of 5 Trustpilot rating based on over 1,000 reviews. This excellent rating is a reflection of the caliber of their offerings and the caliber of customer service they offer.

Positive feedback about HighStreetPharma's products, timely shipping, and top-notch customer support has been left by many consumers who have made purchases there. Customers have claimed that their items arrived on time, with many of them getting their products a week or less after placing their orders. For those who depend on modafinil to treat diseases like narcolepsy or sleep apnea, this short delivery time is crucial.

The products from HighStreetPharma have been praised for their excellent quality in addition to their timely delivery. According to the business, licensed producers and wholesalers are where they get their medication, guaranteeing the best possible quality for their goods. Customers have experienced excellent interactions with the drug, and many say it has helped them properly manage their conditions.

Finally, numerous customers have praised HighStreetPharma's customer service. Customers who may have questions or problems can get help from the company's helpful customer support staff. Customers have stated that they received prompt and obliging responses to their queries, which increased their sense of security and comfort during the purchasing process.

Overall, HighStreetPharma's sitejabber rating and favorable client feedback are a tribute to the caliber of their goods and the kind of customer service they offer. They are a dependable and trustworthy option for people looking to buy modafinil online as a result of these features.

Customer Service

HighStreetPharma values good customer service and works hard to make every client's experience satisfying Customers can always reach out to the company's experienced and helpful customer care staff with any inquiries or issues. Customers can get in touch with the business by phone, email, or live chat, and responses are frequently provided extremely quickly.

HighStreetPharma offers helpful customer assistance in addition to a comprehensive FAQ area on its website. This section addresses a variety of subjects, such as ordering and payment, shipping methods and times, and product details. Customers can immediately obtain answers to their inquiries or address their complaints in the FAQ section without having to get in touch with customer care.

The company's dedication to openness is another feature of HighStreetPharma's client service. The business offers comprehensive details about its products, including the components, dosage, and adverse effects. Customers may be sure that the information they are receiving regarding the pharmaceuticals they are buying is correct and trustworthy.

Ordering Process and Payment Options

The ease and simplicity of HighStreetPharma's ordering process is only one of its many advantages. Customers will find it simple to explore and find the things they need on the company's website. Customers can easily add the desired products to their cart and continue to checkout thanks to the ordering procedure' simplicity.

Customers have a variety of payment methods after selecting the goods they want, including credit card, debit card, and bitcoin. Customers have options and can select the one that is both convenient and secure for them thanks to the variety of payment methods available.

To ensure that customer data is safeguarded during the ordering and payment process, HighStreetPharma has incorporated a number of security mechanisms on their website. This includes establishing two-factor authentication for clients who choose to pay with cryptocurrencies and employing SSL encryption to safeguard sensitive data, such as credit card information.

Once an order has been dispatched, the business also offers consumers complete tracking information so they can follow the progress of their cargo and know when to anticipate arrival.

Overall, HighStreetPharma's website's ordering procedure is easy, secure, and practical. Customers can quickly locate the goods they require, select from a variety of payment methods, and easily track their shipment, making the entire process simple and stress-free.

FAQs On HighStreetPharma

Does HighStreetPharma offer Nootropics only?

The business sells a range of brands of nootropics such as Modafinil that improves attention, concentration, and alertness. Modalert, Modvigil, and Waklert are just a few of the HighStreetPharma's Modafinil brands that are renowned for their high caliber and potency. Apart from that they also stock various medications for other purposes such as skincare, asthma, lifestyle and wellness etc. 

Does HighStreetPharma offer shipping guarantees worldwide?

Although it is only available in a few countries, HighStreetPharma does indeed offer guaranteed shipment. On their website, under shipping, a list of countries is specifically listed. Deliveries are made to the rest of the nations, although in the event of customs surveillance, reimbursements might not be possible.

Does HighStreetPharma have secure payment methods?

For first-time customers who are hesitant to make a purchase from HighStreetPharma's website, they can choose from a variety of payment methods like Mastercard, PayPal, and electronic checks. Gift cards and cryptocurrency payments are favored methods for long-term HighStreetPharma customers who frequently make purchases because of the minimal processing fees and discounts.

Does HighStreetPharma have responsive customer service?

HighStreetPharma is renowned for its devoted customer care, which patiently attends to customer service and attends to every inquiry.

What are the shipping times from HighStreetPharma?

This vendor's typical shipping duration is 12 to 21 days. It might even be less for other nations, including the US.Once the product has been dispatched, the tracking becomes active and is shared with customers right away.

How to Safely Buy Medication Online from HighStreetPharma

Online drug shopping carries some hazards, but there are precautions you can take to make sure you are ordering safely from HighStreetPharma. Here are a few advices:

Do your research: Before making a purchase, learn as much as you can about the business and the item you intend to acquire. Look for testimonials and comments from prior clients;

Verify the medication's authenticity to ensure that it is genuine and has not been tampered with;

Use a secure payment method: To safeguard your personal information, use a secure payment method, such as a credit card or PayPal;

Use a secure payment method: To safeguard your personal information, use a secure payment method, such as a credit card or PayPal;

Visit a healthcare professional before using any medicine, including modafinil: It's crucial to visit a healthcare professional before taking any medication. They can advise you whether the medicine is suitable for your condition and keep an eye out for any possible adverse effects. visit the social media of Highstreetpharma for more updates.

Conclusion

In conclusion, HighStreetPharma is a superb option for anyone searching to purchase prescription medications online. The company's extensive assortment of prescription medications, quick shipment, and top-notch customer service demonstrate its dedication to quality, affordability, and customer pleasure. You can rely on HighStreetPharma to provide you with high-quality medication because a team of qualified pharmacists oversees the safety and effectiveness of all goods.

Due to this, HighStreetPharma is a popular pick for professionals, business owners, and students seeking to gain a competitive advantage in their field of endeavor.

Additionally, consumers who require their prescription soon benefit greatly from the company's speedy shipment dates. With the majority of purchases arriving between 7 to 14 days, HighStreetPharma provides both standard and expedited shipping options. While express shipping is an additional cost, it might be a great option for people who need their medication right away.

Another significant benefit for customers is HighStreetPharma's top-notch customer service. Your queries can be answered and problems can be resolved by the company's staff of customer care specialists. HighStreetPharma makes it simple to receive the assistance you require, whether you prefer to get in touch by phone, live chat, email, or another method.

In conclusion, we heartily endorse HighStreetPharma to anyone wishing to order prescription medications online. HighStreetPharma is a top option for anyone looking for safe, dependable, and economical medication thanks to its extensive product range, quick shipment times, and exceptional customer support.

[a-cure-for-hysteria]

A RANT ABOUT PARTY DRUGS AND PSYCHIATRIC DRUGS

(Expect little cohesion, don’t want to edit this after writing)

Another thing about medicine (both psychiatric and otherwise) is the lies we - collectively - tell ourselves about them. After seeing Dopesick on HBO, even my most conservatives relatives would agree that it’s “such a shame about that girl” and “who’s to say we wouldn’t end up like that with her life”. Basic empathy - finally - but bear with me.

The characters in Dopesick are pretty much fine until they are so tolerant or have been on Oxy so long that no doctor is willing to prescribe more. Then, they’re off to the streets, doing anything they can for oxy, heroin, later fentanyl. The only thing they had in common was some sort of injury happen to them, and a doctor sponsored by Purdue Pharma.

Personally, I have (due to a long list of diagnoses, of which none have been revoked as I got new ones, for some reason) automatically renewed prescriptions in almost all the drug categories. I have amphetamines, cannabinoids, zolpidem, pregabalin and benzodiazepines. If I ask nicely and have a good reason, I get Oxy too - luckily for me, my body has some sort of allergic reaction to opioids, so addiction is unlikely.

However, my cornucopia of legally prescribed substances is a constant, looming threat to my continued well-being, made even more so by the fact that I need them to survive. I just have to NOT go overboard. Sometimes that’s easy, sometimes it’s hard.

I’m 30-something now. I live a pretty calm life - child free with cats and a loving partner, somewhere in rural Northern Europe. Before that, I partied hard. I’ve tasted all the substances for fun (and later; out of social necessity) and let me tell you - the effect I get from a rail of amphetamine snorted from a CD cover at 02:47 AM on a Wednesday, at a party (three tweakers in a dirty apartment) I’d never attend sober… that clear, ready feeling, it’s the same as what I get from 60 mg of Vyvanse each morning.

“People with real ADHD don’t get high from their meds!” you might say. Your ignorance is forgiven. There is so much we don’t know about the brain, about ADHD (if it’s even ONE thing and not several, if it’s generic or trauma or both) and let me tell you - me being high on my meds IS what makes me do the dishes. Go to work. Remember how my partner feels before I take all the dinner scraps without asking if they’ve eaten. I am high. I have taken speed at parties and I know. Every day, I know.

There is no inherent difference between the speed you do at a party and the speed your doctor gives you. Sometimes prescribed speed is tied up with lysine, making you wait an hour before it kicks. Sometimes you get BAD speed at parties - levoamphetamine and not dextroamphetamine. Sometimes it’s cut with bad stuff. But - it’s the same. It’s the same it’s the same it’s the same.

I am as addicted as the guy living under the bridge. However, I get to call it meds and everyone is so happy about my go-getter attitude at work, and how I am a valuable asset to the company. My partner rejoices upon learning I now do my half of the chores. My mom says I seem happier, more well-adjusted. A friend tells me she considered just leaving me alone because I never seemed to get my shit together, but now my shit IS together. Nice!

I recently upped my dose from 30 to 2 x 30 mg Vyvanse. No problem - it even says so on the prescription that I can. I’ve been taking out two boxes at the pharmacy every month, but haven’t taken the correct dose since I started. I just didn’t need to, except now and then on stressful days. Now I need 60 mg, and it doesn’t even feel like 30 did in the start. What happens when 60 is no longer enough for me to feel the high that allows me to get anything done? And, am I lying to myself? Would 30 have been fine? I need, need, need the clear, ready feeling. And I need to get shit done. I need people to be happy with me.

Yes, that’s it. I need people to be happy around me. Is there a rehab for that?

[submalevolentgrace]

"More than a decade ago, investment experts James Altucher and Douglas Sease wrote a book for the Wall Street Journal called Investing in the Apocalypse. They argued that the end of the world is a profitable opportunity for those who know how to “fade the fear”, as everyone else panics. They maintained that when disaster strikes, investors should approach it with the rationale that “no matter how bad things seem, they really aren’t that bad”.

Well before the COVID-19 pandemic, they advised investing in big pharmaceutical companies as a strategy to reap dividends from global pandemics. They also encouraged putting money into renewable energy systems while ramping up oil production.

Today, it seems many have followed Althucher and Sease’s advice. Under the guise of taking action on the pandemic, billions of dollars have been poured into big pharma, instead of public health and policies aimed at preventing another global outbreak. The supposed energy transition that has been undertaken has seen renewable energy production expanded, but there has been no indication that oil and gas are being substituted and ultimately phased out.

What is worse, governments and corporations have teamed up to turn the apocalypse into a money-making opportunity. They have rushed to put forward false solutions to the climate crisis: from the push to replace fuel-engine vehicles with electric ones, to so-called climate-smart agriculture, to protected areas for nature conservation and massive tree planting projects for carbon offsets.

All this trickery is called “greening” and it is designed to profit off of climate fears, not stop climate change. While guaranteeing high returns, this deception is tantamount to the genocide of the hundreds of millions of people who will perish from the effects of climate change within the next century because things are that bad."

[withoutalice]

You wanted ask drabbles and idk like character limits so could I request a Tarnma fluff drabble?

Tarnma fluffyness <3

Word Count: 880

Warnings: none! just a really sweet date night with some sillies

Pharma had always dreamed of being one of those mecha, you know, the kinds that go to grand theater shows and masquerade balls and galas; he was made to be dramatic. Day in and day out it was logic and procedures and direction. He was a forged medic, very skilled at his craft, but he wanted mystery and allure in his life. At night he was able to listen to music, closing his optics and pretending he was lounging in a velvet VIP theater box seat, high above the commoners while indulging in the sweet arts of performance and entertainment.

Pharma sipped on deep red engex, enjoying the peace of his dark office. It was after hours, all the other medics had gone to their quarters for the night. Soon, he heard those familiar stomping pede-steps approaching. He continued nursing his drink, smirking when Tarn opened his unlocked office door.

“Here for your T-cogs?” Pharma sneered. Tarn cleared his throat.

“Actually, I had another request of you.” Pharma rolled his eyes. Tarn ignored it and continued. “Would you be willing to join me for a night?” Pharma hesitated.

“A night of what?”

“It’d be a surprise…” Pharma cackled.

“Hold on, you think I’d just…go?! With the terrifying leader of the DJD without some sort of plan?”

“I assumed, since you’re a flier frame, that you’d be more inclined to act upon impuls-”

“Of course I’ll go!” He snapped. Pharma muttered under his breath as he finished his drink. “Do I look like a square to you? No? Anyway, what should I bring…” Tarn paused for a minute.

“Nothing, unless you have a favorite accessory or other…polish you like to wear out. I’ll give you a few minutes.”

Pharma just opened a drawer and put on magnetic clips to his audials, and used a pocket polish for the corners of his optics and lips.

“No need, let’s go.”

Once they arrived at the location of Tarn’s choosing, the DJD’s leader’s air completely changed. First, he walked over to the side of the transport to open the door for Pharma. Pharma cautiously stepped out, eyeing Tarn suspiciously. After Pharma stepped out of the vehicle, Tarn took Pharma’s arm and servo, walking along with him, clawing servo on the flier's waist. Pharma blushed.

“I-is this some sort of trick?”

Tarn ignored him. They rounded the street corner, exposing them to a grand old building fit with statue-topped columns. It was obviously a theater hall meant to mimic old Cybertronian life. Pharma turned to Tarn in shock.

“How’d you-”

“I saw your collection of tapes and music, figured this would be something you would enjoy…” Pharma was speechless.

“A-are we going to a real show?” Tarn smiled with his eyes and just continued walking down the street, leading the medic. Tarn picked up their tickets at the entrance; Pharma admired the art around the venue hall. 

“You know, I would've put on some better polish on if I'd known.” Pharma jested. Tarn traced the jet’s jawline with a thumb and forefinger admiringly.

“Oh, but I think you always look elegant…natural beauty is very rare.” He blushed again, shaking his helm out of the touch. The DJD leader put his servo guidingly on Pharma’s waist again; he leaned into the hold this time.

Tarn had not only bought them the late night performance tickets, but also seats in the VIP box. Pharma was shocked at how the tank seemed to read his mind, even when he was not around (or, maybe he was…he didn’t dwell on it). Still in awe of the scene, the jet let himself be guided into one of the plush benches, settling into the sound of the orchestra. Tarn watched his face; Pharma’s optics were wide, darting around, studying the architecture and categorizing all the historical pieces and art forms and musical numbers played. 

Throughout the show Pharma slowly started to lean into the leader more, but he never looked up at him. Tarn did his best to understand the show, but to be honest it really wasn’t in his style. He’d only planned this just to spend time with the medic.

Of course, on the way back Pharma did his best to explain his analysis of the story and the value of the original writing. Once they were back at Pharma’s work, the leader uncharacteristically made sure he made it inside safely; he waited at the doorstep for an extra moment.

“Sorry, I almost forgot…thank you. I really enjoyed…uh…whatever tonight was.” Pharma said sheepishly, opposite of his passionate rant earlier.

“What do you think it was?” Tarn rumbled. Pharma vented sharply.

“Oh…well. Fine, it was a ‘date’ ok. Are you happy with that?”

The leader nodded slightly. Pharma couldn't tell if he was blushing under the mask or not, but his body-language showed it was likely. The jet gestured to Tarn to come closer. He pulled the other’s helm down by the side of the mask, lifting the bottom just slightly up. He could feel Tarn's venting still when he kissed those scarred lips, even if it was just for a second.

“Goodnight, Tarn.” The tank adjusted his mask, eye’s still wide in surprise at the show of affection. Tarn cleared his vocalizer.

“Yes…goodnight – !”

The door shut loudly in his face.

[leebird-simmer]

All About: Opioids

- Opioids are substances that act on opioid receptors to produce morphine-like effects.

- Opioids include opiates, an older term that refers to the drugs derived from opium, including morphine.

Opioids = Narcotic Analgesics

- The opioid drugs are narcotic analgesics:

sleep-inducing (narcotic)

pain-relieving (analgesic)

- They are the best painkillers known to humankind, and they also produce a sense of euphoria.

- They create a sense of relaxation, but at high doses, they can lead to coma and death.

Opium

- Opium has been used recreationally and in medicine for thousands of years (since 5000 BC in China).

- Opium is an extract of the poppy plant (Papaver somniferum).

- Opium is prepared by drying and powdering the milky juice taken from the seed capsules of the opium poppy just before ripening.

- Opium contains morphine, codeine, thebaine, narcotine, and other ingredients.

- Recreational users often smoke opium for its rapid absorption from the lungs.

Opium-Based Products

- Laudanum, an opium-based medicinal drink, was introduced to England in 1680.

- Drinking laudanum-laced wine was the accepted form of opium use in Victorian England & USA.

- Up to the 20th century, laudanum was common in popular remedies.

Morphine

- extracted from the poppy plant in 1805 by a German chemist named Friedrich Serturner

- It was the first time an active ingredient of any medicinal plant was isolated.

- Extraction of morphine allowed doctors to prescribe it in known dosages.

- very powerful analgesic and euphoric drug

- named after Morpheus, the Greek god of dreams

Codeine

- isolated in 1832

- less analgesic effect and fewer side effects than morphine

- A potent cough suppressant, it is often included in cough medicine and in pain relievers.

Heroin

- was developed by the Bayer Company in 1874 to be more effective in relieving pain and cough without the danger of addiction.

- Heroin was made by adding two acetyl groups to morphine, making it more lipid soluble. The very rapid action of heroin is responsible for the dramatic euphoric effects achieved with that drug.

- as a street drug, preferred over morphine

- pharmacological effects of morphine and heroin are essentially identical because heroin is converted to morphine in the brain.

Oxycodone

- semisynthetic opioid derived from thebaine

- In 1916, German scientists at the University of Frankfurt developed oxycodone as an analgesic less addictive than morphine.

- Oxycodone was approved by the FDA in 1950 as Percodan (mix of oxycodone & aspirin).

- Since the early 1960s, abuse of prescription opioids containing oxycodone has been a major concern in the USA.

- In 1996, Purdue Pharma introduced (and aggressively marketed) OxyContin, a controlled release formulation of oxycodone.

- Purdue advertised Oxycontin as non-addictive because the drug was designed to be released within the body over a 12-hour period.

- Recreational drug users quickly learned to get high by crushing or dissolving these time-release pills.

- Spread of Oxycontin abuse has resulted in increased deaths from overdose.

Molecular structure of morphine, codeine, heroin, and naloxone

Selected natural and synthetic opioid drugs

Heroin = Schedule I

Morphine, oxycodone, fentanyl, opium, methadone = Schedule II

Opioids: Routes of Administration

- Recreational users often smoke opium for its rapid absorption from the lungs.

- Morphine:

in hospitals: intravenous, intramuscular, or subcutaneous injection; or given orally

in the streets: inhalation

- Oxycodone, vicodine: taken orally as pills

- “Snorting” heroin leads to rapid absorption through the nasal mucosa. Subcutaneous administration (”skin popping”) may precede the more dangerous “mainlining” (IV injection).

Opioids: Distribution

- Morphine and oxycodone have similar fat-solubility and only a small fraction of the drugs can cross the blood-brain barrier.

- Heroin and fentanyl are much more fat soluble and can reach the brain faster. They are much more potent when injected.

- Opioids easily cross the placenta. Newborns can suffer withdrawal symptoms but can be stabilized with low doses of opioids.

Opioids: Metabolism

- Morphine reaches peak levels with oral administration within 60 minutes; with IV injection, within 15 minutes. The drug has a half-life of about 90 minutes to 3 hours.

- Fentanyl: with IV injection, peaks in 1 minute; half-life of 1.5 hours.

- Oxycodone: oral administration peaks in 30-60 minutes (controlled release 3 hours); half-life is 3-5 hours.

- Oral administration: first-pass metabolism in the liver reduces the bio-availability of opioids.

- Most opioids are metabolized via CYP-mediated oxidation (codeine, oxycodone, methadone) and have substantial drug interaction potential (with the exception of morphine).

Opioids: Excretion

- After metabolism in the liver, most opioid metabolites are excreted in the urine within 24 hours.

- Typically, morphine can be detected in urine for 1-2 days. In cases of heavy or chronic use, morphine might be detectable for slightly longer, but it usually can’t be detected after about 4-5 days.

Pharmacodynamics: Effects of Opioids

- Effects of opioids on the CNS are related to dose and rate of absorption.

- Low to moderate doses result in:

pain relief (analgesia)

relaxation

dreamy sleep

- Some researchers suggest morphine relieves anxiety, aggression, and feelings of inadequacy. This may lead to more drug use.

- At higher doses, there is an abnormal state of elation or euphoria, described as a “kick,” “bang,” or “rush.” This acts as a powerful reinforcer that encourages repeated drug use.

Pharmacodynamics: Side Effects

(A) Behavioral

- drowsiness, inability to concentrate

- (rarely) adverse effects, such as dysphoria, restlessness and anxiety

- At highest doses, the sedative effects may lead to unconsciousness.

(B) Physiological

- constricted pupils

- nausea and vomiting. Opioids affect the area postrema in the brain stem that elicits vomiting.

- constipation: Opium and morphine have been used to treat diarrhea and can be life-saving to stop fluid loss in severe bacterial and parasitic diseases.

Opioid Overdose

- at highest doses = respiratory depression. In recreational users, tolerance to euphoria develops faster than to respiratory depression.

- Opioids act on the brain stem’s respiratory center; respiratory failure is the ultimate cause of death in overdose.

- sedative effects may lead to loss of consciousness.

- body temperature and blood pressure fall

- pupils become very constricted

- antidote = naloxone (Narcan)

Opioid agonists = morphine, oxycodone, fentanyl, etc.

Opioid antagonists = naloxone, naltrexone

Neurochemical Effects: Receptors and Endogenous Opioids

- Our bodies synthesize our own analgesic substances: endogenous opioids (endorphin, enkephalin, dynorphin)

- Endogenous = produced in our body

- discovered in 1974

- produced in response to pain, but also to exercise, laughter, etc.

- Both opioid drugs and endogenous opioids produce their effects via endogenous opioid receptors in the CNS.

Analgesia - medial thalamus, periaqueductal gray (PAG), median raphe, spinal cord

Positive reinforcement - nucleus accumbens, VTA

Cardiovascular and respiratory depression, cough control, nausea and vomiting - brainstem

Opioids: Mechanism of Action

- Opioid receptors are metabotropic.

- Opioids inhibit nerve activity in multiple ways:

Postsynaptic inhibition - receptors activate a G protein that opens K+ channels to hyperpolarize the post-synaptic cells, reducing firing rate.

Axoaxonic inhibition - receptors activate G proteins that close Ca2+ channels, reducing the release of neurotransmitter.

Pain Pathways to the Brain

- How do we feel pain?

- Painful stimuli can be detected by special receptors (nociceptors) located all over our body (including in our skin).

- Sensory information is sent through the spinal cord to the brain, where painful sensation is formed.

- Nociceptors --> Spinal cord --> Thalamus --> Cortex

Pain Management

- Multiple regions in the brain can suppress activity of the pain sensory neurons in the spinal cord.

- PAG (periaqueductal gray) is the key structure.

(I) Opioids stimulate neurons in the PAG that are responsible for inhibition of the pain sensory neurons in the spinal cord.

(II) Opioids directly inhibit the pain sensory neurons in the spinal cord.

(III) Opioids also affect higher sensory areas, hypothalamus and limbic structures in the brain.

Opioids: Reward Pathway

Reward pathway: mesolimbic: VTA ---> Nacc

- Opioids suppress GABA synapses on VTA dopaminergic neurons

--> Disinhibition --> Increase in firing --> Increase in dopamine release in Nacc

- Experiment: opioids micro-injected into the VTA increase dopaminergic cell firing

- Continued activation of the dopaminergic reward pathway leads to the feelings of euphoria and the ‘high’ associated with opiate use

Chronic Use of Opioids

- Chronic use of opioids leads to neuro-adaptive changes, which are responsible for tolerance, sensitization, and dependence.

- Opioids have significant reinforcing properties.

- Opioids effectively produce tolerance.

- Cross-tolerance among the opioids also exists.

- Example: after chronic heroin use, codeine will elicit a milder-than-normal response even if the individual has never used codeine before.

- Physical dependence: neuro-adaptive state in response to long-term occupation of opioid receptors.

- Physical dependence does not necessarily lead to abuse or addiction.

- When the drug is no longer present, cell function returns to normal and overshoots basal levels. Effects are seen in withdrawal symptoms (abstinence syndrome).

- Opioids in general depress CNS function; opioid withdrawal is rebound hyperactivity.

- Abstinence signs reflect a loss of inhibitory opioid action at all receptors in the CNS and elsewhere, as blood levels of the drug gradually decline.

- Severity and time course of withdrawal symptoms can vary with many factors, including the particular drug used:

Heroin: peak within few minutes; withdrawal may begin within 6-24 hours of discontinuation of the drug

Methadone: gradual increase over several days and a gradual decrease over several weeks

- Drug’s time frame can fluctuate with the degree of tolerance as well as the amount of the last consumed dose.

- Withdrawal symptoms can also be classically conditioned.

- The high rate of relapse may be due to the conditioned abstinence syndrome in the old environment.

- Some addicts describe withdrawal symptoms when they visit areas of prior drug use, even years later.

Opioid Addiction

DSM-5: Opioid Use Disorder

- A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least two of the 11 criteria, occurring within a 12-month period.

Treatment

- A multidimensional approach includes detoxification, pharmacological support, and group or individual counseling.

- Counseling helps addicts identify the environmental cues that trigger relapse and design a behavioral response to those cues.

- Narcotics Anonymous is another option, based on the program for alcohol abuse.

Detoxification is the first step, which can be assisted by opioids such as methadone and buprenorphine (opioid receptor agonists):

substitutes for heroin

reduce symptoms to a comfortable level

Methadone maintenance program:

The most common and effective treatment for heroin addiction. Relieves craving for heroin.

Methadone is long-acting, producing a constant level of drug in the blood.

Methadone has cross-dependence with heroin, which prevents severe withdrawal symptoms.

Methadone can produce a “high” if injected, which could lead to illegal diversion of the drug.

Thus, programs require daily supervised oral administration. Little or no euphoria occurs with oral administration.

Oral administration reduces use of the needle by the addict and the ritual surrounding its use.

- Some treatment programs use narcotic antagonists (= opioid receptor antagonists).

Naltrexone (Trexan) is most commonly used because it has a longer duration of action than naloxone, is effective when taken orally, and has few side effects.

This method is effective for highly motivated individuals. Craving for the drug is not eliminated, so most less-motivated addicts stop antagonist treatment and return to drug use.

Experimental Treatment:

A vaccine is being developed to produce antibodies that would bind to the drug molecules in the blood circulation and prevent entry into the brain.

A vaccine that recognizes heroin and its active metabolites has been tested in rats.

[transparencymarketresearch1]

Cleanroom Equipment Market by Size, Growth, Trends and Forecast – 2031

The global cleanroom equipment market is projected to experience significant growth from 2023 to 2031. Cleanroom equipment plays a crucial role in maintaining sterile environments in various industries such as healthcare, pharmaceuticals, biotechnology, and electronics manufacturing. The market is driven by the increasing demand for advanced healthcare facilities, stringent regulatory standards, and the growing focus on research and development activities.

Market Size and Growth: The global cleanroom equipment market is expected to witness significant growth during the forecast period. Factors such as the increasing adoption of cleanroom technology in the healthcare sector, the rising demand for pharmaceutical and biotechnology products, and the growing semiconductor industry are driving market growth.

Request For a Sample Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85691

Market Segmentation: By Service Type:Cleanroom EquipmentCleanroom Consumables

By Sourcing Type:In-houseOutsourced

Market Drivers and Challenges:

Drivers: Increasing demand for quality healthcare facilities, stringent regulatory standards, growing pharmaceutical and biotechnology industries, and technological advancements in cleanroom equipment.

Challenges: High cost of cleanroom equipment, complex regulatory requirements, and lack of skilled professionals.

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=85691&ltype=S

Competitive Landscape: The global cleanroom equipment market is highly competitive, with several key players dominating the market. Some of the major players in the market include AccumaX India, ACMAS Technologies (P) Ltd, Aircare Projects Pvt. Ltd, Airomax Airborne LLP, Bionics Scientific Technologies (P) LTD., Brinda Pharma Technologies, K J Pharmatech, MRC Systems FZE, Pharma Air Modular Systems.

About Us:

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

[brightonashford123]

Choosing the Third-Party Lab with the Best Back End

White Paper

by , Brent Ristow, PhD, JD

On February 20, 2024 the FDA released a letter titled “Fraudulent and Unreliable Laboratory Testing Data in Premarket Submissions … reminding sponsors to carefully evaluate the third parties they engage to conduct performance testing and to independently verify all testing results before submitting to the FDA.”

Third-party labs are going through a period of mergers and acquisitions. Equity groups Waters Street and Leonard Green purchased, and are struggling to integrate, labs to create entities capable of servicing the full phase of FD&C development and commercialization.

The scientists at the benchtop of these third-party labs cover a diverse range of technical experience and education. The vast majority of them, however, will have recently obtained an undergraduate degree in a relevant discipline. One third-party testing lab, having gone through a position survey following internal employee revolt, raised starting pay for these recent graduates to $22/hr. In April, 2024, California fast food workers will start at $20/hr.

These benchtop scientists work long hours repeating a variety of highly technical tasks. But with the variety of services offered by these labs, the recent graduate, hopefully, gets exposed to an array of experts and techniques. While the recent graduate gets a diversity of experience the labs get samples analyzed, projects billed, and, hopefully, monthly budget met.

With a growth in major pharma reliance on third-party labs, some labs are establishing revenue growth goals of 30% year over year. With these goals these entities are under pressure to get samples in and data out. This pressure combined with poor pay for a highly technical discipline and industry growth leads to these labs experiencing high turnover. Positions populated by those recent graduates experience turnover that fluctuates, on a monthly basis, between 12 to 25%; one major lab recently saw turnover of 42%!

What this means is that when interacting with a third-party lab, if they are cGMP compliant, there will always be chaos lurking in the background. I’ve seen PhD principal chemists leave to play professional hockey, make kids video games, and open a dance club, all early in their careers. And so, in the middle of your project analysts, QA specialists, etc. will likely be leaving. How do you pick the right lab?

When interviewing a lab ask them about trends in their laboratory investigations, those required by cGMP compliance. All labs will have investigations, and analyst turnover will contribute to the total number of investigations. But, trend indicating an ongoing increase in investigations may be a sign that the lab you are interviewing lacks sufficient back end processes and support in targeting, recruiting, onboarding, training, and mentoring, and in the keeping of quality laboratory personnel.

Because your FD&C project is likely a years-long endeavor it would be wise to use a third-party lab with sufficient back end to support your project. Asking about trends in turnover and laboratory investigations is a good place to start as any.

Brent Ristow, PhD, JD

Founder, Brighton Ashford, LLC

Boutique Pharma & Med Device Consulting

[market-spy]

Multiple Myeloma Therapeutics Market: Growth and Challenges

In the ever-evolving landscape of healthcare, where the buzzwords are usually as exciting as watching paint dry, the global Multiple Myeloma Therapeutics Market has decided to break the monotony. Buckle up, because we’re about to take you on a thrilling ride through the fascinating world of multiple myeloma treatment, where science meets survival, and the stakes are high.

A Rollercoaster of Growth: From $26.69 Billion to $47.04 Billion!

Hold onto your seats, folks, because we’re talking serious numbers here. The market size for multiple myeloma therapeutics skyrocketed from a humble USD 26.69 billion in 2022 to a whopping USD 47.04 billion in the mystical year of 2031. That’s a CAGR of 6.5%, making Wall Street traders wish they’d invested in plasma cells instead of GameStop.

Why the Sudden Surge? Blame it on Aging and Science!

Wondering why this market is experiencing a growth spurt that could put teenagers to shame? Well, it seems the aging population is playing a key role. As people get older, the likelihood of dancing with the devil called multiple myeloma increases. It’s like the disease is sending out invitations to join the party, and everyone over a certain age is on the guest list.

But hold your horses; it’s not just about growing old gracefully. The real MVP here is science. We’ve gone beyond the basics of knowing multiple myeloma exists; now, we’re delving into its molecular intricacies. It’s like we’ve upgraded from playing checkers to a high-stakes game of chess with cancer cells. The result? Specialized medicines and treatments that are more potent than grandma’s secret chili recipe.

Therapeutic Techniques: The Avengers of Multiple Myeloma

Now, let’s talk about the superheroes fighting the villainous multiple myeloma. Picture this: stem cell transplants, immunomodulatory medications, proteasome inhibitors, chemotherapy, monoclonal antibodies, and supportive therapies — a formidable league of extraordinary treatments. Move over Avengers; the real action is happening in the bone marrow.

Market Snapshot — North America Leading the Charge

If the global multiple myeloma therapeutics market were a race, North America would be leading the pack like it stole the checkered flag. With a healthcare system that’s as intricate as a Shakespearean play and R&D investments that could make Elon Musk blush, North America is the undisputed champion.

But wait, there’s an underdog in this story — the Asia-Pacific region. With better access to healthcare, increased medical investments, and a growing understanding of multiple myeloma, this region is giving North America a run for its money. It’s like the healthcare version of ‘David vs. Goliath,’ only with fewer slingshots and more clinical trials.

For More Information: https://www.skyquestt.com/report/multiple-myeloma-therapeutics-market

Market Dynamics: The Good, the Bad, and the Expensive

Now, let’s address the elephant in the room — the cost of treatment. While we’re busy celebrating advancements in medicine, some of these treatments can be as expensive as a beachfront property in the Hamptons. High treatment costs might make you question whether fighting multiple myeloma is worth the financial battle.

Then there’s the complexity of the disease itself. Multiple myeloma isn’t your run-of-the-mill illness; it’s more like a Rubik’s Cube of genetic and molecular characteristics. Each patient is a unique puzzle, and finding the right combination of treatments can be as tricky as solving that cube blindfolded.

The Competition: Big Pharma’s Battle Royale

In the world of multiple myeloma therapeutics, it’s survival of the fittest. Big names like Johnson & Johnson, Amgen Inc., and Bristol Myers Squibb are flexing their research muscles to develop cutting-edge treatments. Partnerships and alliances are formed faster than you can say “monoclonal antibodies,” and the goal is clear — offer patients a fighting chance, a better quality of life, and a longer lease on life.

Recent Developments: FDA Approvals and the Game-Changers

Imagine the FDA as the gatekeeper of a mystical realm, and recent developments are the golden keys unlocking new possibilities. CAR T-cell treatments, bispecific antibodies, CD38 inhibitors — it’s like a pharmaceutical Renaissance, where each approval is a stroke of genius on the canvas of medical innovation.

Key Market Trends: Immunotherapies, Targeted Therapies, and Personalized Medicine

Move over, traditional treatments; immunotherapies and targeted medicines are stealing the spotlight. It’s like replacing your flip phone with the latest smartphone — more efficient, more effective, and definitely cooler. Plus, there’s a growing emphasis on personalized medicine, where biomarkers and genetic profiling play the role of matchmakers, pairing patients with treatments tailored to their unique disease characteristics.

Conclusion: The Thrill Ride Continues

In the realm of multiple myeloma therapeutics, the rollercoaster of growth, challenges, and breakthroughs keeps us on the edge of our seats. It’s a journey where science meets humanity, and the ultimate goal is to rewrite the narrative of multiple myeloma from a deadly disease to a conquerable foe.

So, as we ride the wave of advancements, approvals, and market dynamics, one thing is certain — the global multiple myeloma therapeutics market is not just a business venture; it’s a quest for life, longevity, and the triumph of science over adversity. Buckle up, because the thrill ride continues, and the best is yet to come.

About Us-

SkyQuest Technology Group is a Global Market Intelligence, Innovation Management & Commercialization organization that connects innovation to new markets, networks & collaborators for achieving Sustainable Development Goals.

Contact Us-

SkyQuest Technology Consulting Pvt. Ltd.

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 617–230–0741

Email- info@skyquestt.com

Website: https://www.skyquestt.com

[sqinsights]

Multiple Myeloma Therapeutics Market: Growth and Challenges

In the ever-evolving landscape of healthcare, where the buzzwords are usually as exciting as watching paint dry, the global Multiple Myeloma Therapeutics Market has decided to break the monotony. Buckle up, because we’re about to take you on a thrilling ride through the fascinating world of multiple myeloma treatment, where science meets survival, and the stakes are high.

A Rollercoaster of Growth: From $26.69 Billion to $47.04 Billion!

Hold onto your seats, folks, because we’re talking serious numbers here. The market size for multiple myeloma therapeutics skyrocketed from a humble USD 26.69 billion in 2022 to a whopping USD 47.04 billion in the mystical year of 2031. That’s a CAGR of 6.5%, making Wall Street traders wish they’d invested in plasma cells instead of GameStop.

Why the Sudden Surge? Blame it on Aging and Science!

Wondering why this market is experiencing a growth spurt that could put teenagers to shame? Well, it seems the aging population is playing a key role. As people get older, the likelihood of dancing with the devil called multiple myeloma increases. It’s like the disease is sending out invitations to join the party, and everyone over a certain age is on the guest list.

But hold your horses; it’s not just about growing old gracefully. The real MVP here is science. We’ve gone beyond the basics of knowing multiple myeloma exists; now, we’re delving into its molecular intricacies. It’s like we’ve upgraded from playing checkers to a high-stakes game of chess with cancer cells. The result? Specialized medicines and treatments that are more potent than grandma’s secret chili recipe.

Therapeutic Techniques: The Avengers of Multiple Myeloma

Now, let’s talk about the superheroes fighting the villainous multiple myeloma. Picture this: stem cell transplants, immunomodulatory medications, proteasome inhibitors, chemotherapy, monoclonal antibodies, and supportive therapies — a formidable league of extraordinary treatments. Move over Avengers; the real action is happening in the bone marrow.

Market Snapshot — North America Leading the Charge

If the global multiple myeloma therapeutics market were a race, North America would be leading the pack like it stole the checkered flag. With a healthcare system that’s as intricate as a Shakespearean play and R&D investments that could make Elon Musk blush, North America is the undisputed champion.

But wait, there’s an underdog in this story — the Asia-Pacific region. With better access to healthcare, increased medical investments, and a growing understanding of multiple myeloma, this region is giving North America a run for its money. It’s like the healthcare version of ‘David vs. Goliath,’ only with fewer slingshots and more clinical trials.

For More Information: https://www.skyquestt.com/report/multiple-myeloma-therapeutics-market

Market Dynamics: The Good, the Bad, and the Expensive

Now, let’s address the elephant in the room — the cost of treatment. While we’re busy celebrating advancements in medicine, some of these treatments can be as expensive as a beachfront property in the Hamptons. High treatment costs might make you question whether fighting multiple myeloma is worth the financial battle.

Then there’s the complexity of the disease itself. Multiple myeloma isn’t your run-of-the-mill illness; it’s more like a Rubik’s Cube of genetic and molecular characteristics. Each patient is a unique puzzle, and finding the right combination of treatments can be as tricky as solving that cube blindfolded.

The Competition: Big Pharma’s Battle Royale

In the world of multiple myeloma therapeutics, it’s survival of the fittest. Big names like Johnson & Johnson, Amgen Inc., and Bristol Myers Squibb are flexing their research muscles to develop cutting-edge treatments. Partnerships and alliances are formed faster than you can say “monoclonal antibodies,” and the goal is clear — offer patients a fighting chance, a better quality of life, and a longer lease on life.

Recent Developments: FDA Approvals and the Game-Changers

Imagine the FDA as the gatekeeper of a mystical realm, and recent developments are the golden keys unlocking new possibilities. CAR T-cell treatments, bispecific antibodies, CD38 inhibitors — it’s like a pharmaceutical Renaissance, where each approval is a stroke of genius on the canvas of medical innovation.

Key Market Trends: Immunotherapies, Targeted Therapies, and Personalized Medicine

Move over, traditional treatments; immunotherapies and targeted medicines are stealing the spotlight. It’s like replacing your flip phone with the latest smartphone — more efficient, more effective, and definitely cooler. Plus, there’s a growing emphasis on personalized medicine, where biomarkers and genetic profiling play the role of matchmakers, pairing patients with treatments tailored to their unique disease characteristics.

Conclusion: The Thrill Ride Continues

In the realm of multiple myeloma therapeutics, the rollercoaster of growth, challenges, and breakthroughs keeps us on the edge of our seats. It’s a journey where science meets humanity, and the ultimate goal is to rewrite the narrative of multiple myeloma from a deadly disease to a conquerable foe.

So, as we ride the wave of advancements, approvals, and market dynamics, one thing is certain — the global multiple myeloma therapeutics market is not just a business venture; it’s a quest for life, longevity, and the triumph of science over adversity. Buckle up, because the thrill ride continues, and the best is yet to come.

About Us-

SkyQuest Technology Group is a Global Market Intelligence, Innovation Management & Commercialization organization that connects innovation to new markets, networks & collaborators for achieving Sustainable Development Goals.

Contact Us-

SkyQuest Technology Consulting Pvt. Ltd.

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 617–230–0741

Email- info@skyquestt.com

Website: https://www.skyquestt.com

[optionperks]

Small-cap stock below ₹10: Pharma stock Vikas Lifecare hits upper circuit after getting new patent Small-cap stock below ₹10

Shares of Vikas Lifecare is one of the penny stocks listed on the Indian stock market. The small-cap company with a market cap of around ₹961 crore is in the news today for receiving a new patent from the Indian Patent Office for the Innovative Multi-Layered Plastic Recycling Process. The company shared the development with Indian stock market exchanges in an exchange filing. After the spread of this stock market news, Dalal Street bulls started to pump money into the penny stock, which led to no seller in the stock. The small-cap stock below ₹10 hit a 5 percent upper circuit during the morning dealings on Thursday. Vikas Lifecare share price today opened upside at ₹5.80 apiece on NSE and extended its morning gains further. the small-cap penny stock went on to touch an intraday high of ₹6 per share and locked in a 5 percent upper circuit. While climbing to this intraday high, the small-cap penny stock came close to its 52-week high of ₹8 apiece. www.optionperks.com

[prismmediawire]

Exploring Small-Cap AI Opportunities in a Big-Cap Dominated Market

New York, N.Y., January 24, 2024 - The recent rally in artificial intelligence (AI) investments had a notable exception: small caps. The Street’s James “Rev Shark” DePorre noted the stark contrast between the current AI bubble and the more inclusive Internet bubble of the late 1990s in his column “There is an AI Bubble, but There is No Small-Cap Participation.”

He wrote, “During the Internet bubble in 1999-2000…hundreds of small-caps attracted speculative traders and helped drive the frenzy. The AI bubble is nothing like that. […] Traders like me who favor aggressive trading of smaller stocks with good charts and fundamentals feel extremely frustrated with this market action.”

He is not the only expert who recognizes overlooked opportunities in the small-cap world. Historically, small-cap companies have been pivotal in driving market dynamics and investor returns, yet this recent rally has seemingly missed the potential for growth and innovation in smaller stocks.

At PRISM MarketView, we are keenly aware of this gap. Our approach is to identify and highlight small-cap AI stocks, among other key and emerging indices, that show promise but are currently underrepresented in the broader market narrative.

To that end, we have identified three small-cap AI stocks from the PRISM Emerging NextGen Tech index to keep an eye on:

BigBear.ai:

BigBear.ai specializes in decision intelligence solutions powered by algorithms, serving a wide range of clients including the U.S. intelligence community and sectors such as health care and manufacturing. A notable collaboration with Amazon Web Services enhanced BigBear’s AI capabilities in supply chains and logistics. Despite a recent revenue dip due to winding down certain programs and Virgin Orbit’s bankruptcy, BigBear.ai has shown impressive financial resilience. The company successfully reduced expenses, leading to its first net income positive quarter since going public.

Rekor Systems:

Rekor Systems is a company that specializes in providing advanced vehicle recognition systems and solutions. They leverage artificial intelligence (AI) and machine learning technologies to develop software and hardware solutions for license plate and vehicle recognition and other related applications. Rekor has secured three significant public safety contracts totaling to $3M in addition to a five year traffic counting contract with Gwinnett, Georgia’s Transportation Department.

Lantern Pharma:

Lantern Pharmaceuticals is a biotechnology company focused on the discovery and development of precision oncology therapeutics. They utilize a proprietary artificial intelligence (AI)-driven platform to identify and advance novel drug candidates with the potential to target specific genetic and molecular alterations associated with cancer. The FDA has granted Lantern Pharma with orphan drug designation for its drug candidate LP-284 in high-grade B-cell lymphomas (HGBL) and provided its recent financial results citing a productive and efficient third quarter.

While the excitement in the AI sector currently revolves around big names and big companies, small caps may offer big promise and potential for investors in next-gen tech.

The PRISM Emerging NextGen Tech index covers the latest advances in AI, Web 3.0, metaverse and blockchain. Visit https://prismmarketview.com/index/prism-emerging-nextgen-tech/ to learn more.

About PRISM MarketView:

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView does not provide investment advice.

Media Contact Company Name: Prism MarketView Email: info@prismmarketview.com Phone: 646-863-6341 Website: https://prismmarketview.com

[davidrivkin]

The ‘Public Nuisance’ Menace

By David B. Rivkin, Jr., and O. H. Skinner

August 17, 2023, in the Wall Street Journal

Hawaii’s Supreme Court hears oral arguments Thursday in Honolulu v. Sunoco, a lawsuit brought by the state’s largest city against a group of energy companies. Honolulu alleges that the defendants have created a “public nuisance” by producing fossil fuels that emit greenhouse gases when burned. The companies argue that they are already subject to federal regulation, which supersedes any claim under state law.

Activist groups are increasingly attempting to use public-nuisance lawsuits to impose policies that they’ve failed to persuade lawmakers to enact. The list of industries under assault is long and growing. One set of public-nuisance actions targets firearm manufacturers. It was launched on behalf of local governments in New York state by plaintiff lawyers, with the firm Napoli Shkolnik, fresh from a successful action against pharmaceutical companies, serving as lead counsel. Other cases pursue chemical companies for producing so-called forever chemicals, which have been lawfully used for decades in making and packaging countless household and personal-hygiene products.

Public-nuisance lawsuits also attack beverage companies for using plastic bottles, leading to litter on beaches. School districts are suing tech companies claiming that their social-media platforms endanger children. Several cities have sued Hyundai and Kia alleging that certain cars they make are “too easy to steal.”

The financial stakes are high. The opioid cases—brought against drug manufacturers, distributors and retail pharmacy chains—have generated more than $55 billion in settlements. (Last week the U.S. Supreme Court stayed a settlement between plaintiffs and bankrupt Purdue Pharma, pending an appeal that the justices will hear in December.) The litigation against “forever chemicals” manufacturers, which is still in the early stages, has already led to more than $11 billion in tentative settlements. Given the apocalyptic rhetoric around climate change and gun violence, lawsuits against gun and energy companies, if successful, could yield hundreds of billions of dollars in damages.

Their lawsuits feature profoundly flawed theories of liability that threaten the fabric of U.S. law. Under traditional common law, a paradigmatic public nuisance suit involves clearly unlawful conduct, such as running a brothel or drug house in a residential neighborhood, blocking a public right of way, or operating a factory that emits noxious smells. Defendants in such lawsuits are the agents directly responsible for causing the alleged harm.

These new ideological public-nuisance suits target products or activities that didn’t violate any law or regulation at the time they were produced and used. The defendants are manufacturers and distributors rather than individuals who committed specific wrongful acts. Such claims often feature freestanding state-law causes of action, available to local governments that otherwise lack legal authority to bring other public enforcement actions. That enables plaintiff lawyers, working with local governments, to make an end-run around state governments, pushing “progressive” policies, even in conservative states.

As long as the threat of litigation lingers over every industry under the sun, plaintiff lawyers will have the ability to intimidate market participants and reshape the economy without ever scoring a conclusive win in a courtroom (never mind a legislature). Even corporate giants that can afford to fight sometimes find it more economical to settle a meritless claim. Litigation options and their attendant costs are even worse for small and midsize businesses, like local car dealers, gasoline stations and beverage distributors.

There have been some major litigation setbacks to this public-nuisance campaign. In 2021 the Second U.S. Circuit Court of Appeals dismissed a New York City suit against international oil companies that sought to recover, as the court put it, “damages caused by those companies’ admittedly legal commercial conduct in producing and selling fossil fuels around the world.” The same year, the Oklahoma Supreme Court tossed an opioid case against Johnson & Johnson.

But because such lawsuits are usually driven by state law, there is no opportunity for a conclusive nationwide win at the U.S. Supreme Court covering all these lawsuits; the battles have to be waged on a state-by-state basis. Federal constitutional issues arise in cases against some industries—the First Amendment for social media, the Second Amendments for gun makers. There are also some instances in which federal common law or regulatory statutes like the Clean Air Act pre-empt the application of state public-nuisance laws. That was the basis on which the Second Circuit threw out the New York case and is one of the key arguments before the Hawaii Supreme Court.

Fortunately, there are other available remedies. State legislatures could bar cities and counties from hiring plaintiff lawyers to prosecute public nuisance suits on a contingency basis, which would constitute an excellent remedial measure. They could also forbid local governments from bringing public-nuisance cases at all, or at least against manufacturers and distributors of products circulating in interstate commerce, or require approval from state officials such as the attorney general.

Conservative states would likely lead the way in enacting such reforms. These public-nuisance lawsuits harm the economy and are antithetical to American democracy, which requires decisions about economic regulation to be made by politically accountable officials, not by courts. And having governmental entities delegate litigation control to plaintiff lawyers amounts to a government-deputized shakedown of disfavored industries.

Mr. Rivkin practices appellate and constitutional law in Washington. He served at the Justice Department and the White House Counsel’s Office in the Reagan and George H.W. Bush administrations. Mr. Skinner is executive director of Alliance For Consumers. He has served as solicitor general and handled consumer cases in the Arizona Attorney General’s Office.

Source: https://www.wsj.com/articles/public-nuisance-gun-pharma-car-theft-pollution-fossil-fuels-trial-lawyer-settlement-abuse-power-f45a8581

[johnjankovic1]

Gilded Age 2.0

History doesn’t repeat itself but it often rhymes.

Mark Twain

Society’s capture by corporations signals the late stages of capitalism where free markets run roughshod over governments and the public. What abounds is the inexorable creep of business into every facet of life as policy decisions rest in the firm control of monied interests in search of profit with the loss of sovereignty and agency for the elected and electors alike. Each passing year marks a further consolidation and concentration of wealth where income inequality spurs political instability. Not foreign to history is how this very brinkmanship conspires to limp the world into revolution as similarities resonate with the Ancien Régime when deprivation reached a crescendo of resentment for the ruling class amidst the French Revolution. Without confidence a system suffers an erosion to its legitimacy until its proper subversion. Likewise the inordinate clout held by Big Business over politics has had the same effect of sidelining the majority who feel helpless when their job security hinges on the footloose nature of their employers. Such a footprint left by deindustrialization, wage stagnation and automation upon labour markets has ushered the spectre of collapse for middle-income households everywhere.

Everything since has become polarized under the existential threat that is global corporatocracy. The ‘Great Reset’ with its unprecedented transfer of wealth from the poor to the rich marked a nadir of regression in a foil to the immediate postwar boom for the working class. It might be said that society has devolved back to its primitive state under the jackboot of aristocracies from a bygone age. Big Pharma exploited profits to the detriment of public health causing the OxyContin epidemic thanks to a complicit FDA. Big Finance immune to risk cowed policymakers into industry-wide deregulation until the advent of 2008’s Financial Crisis. Big Auto blinkered to fuel economy was left flatfooted after years of protectionism when the high elasticity of demand for SUVs cut payroll on the assembly line. Big Tech manipulated public opinion in a quid pro quo at the behest of politicians in the 2020 election. Big Oil and the military-industrial-complex exported imperialism in the Middle East for oil reserves and defence contracts respectively. The FAA allowed Boeing to self-regulate leading to the crashes of the 737 Max. These examples to name a few bespeak how market capitalization equates with a veto power over the electorate to the perversion of democracy.

What capitalism now approaches is the wild accumulation left for the Robber Barrons at the height of the Gilded Era. Modern companies transcend nationhood to become whole empires with corporate revenue rivalling the GDP of most G7 economies akin to the predation once seen in the railroad, steel, and oil industries when monopolies of upstream and downstream production greatly widened the distribution of wealth. The legacy of these past exploits left a country divided along fault lines between liberalism and populism exactly as it does today. Deregulation, subsidies, legal immunity, protective tariffs and the like were all sought by lavish donations as a form of insurance to maximize those interests presiding over Washington and Wall Street. Such politics in the spirit of Public Choice Theory arouse a species of discontent for the top 1% much like it did then only now it is a symptom of job displacement and scarce labour protections in light of the gig economy and decline in unions. The knowledge economy appears to be a facsimile of the industrial one. Of particular note is how this centennial cycle mimics the fortunes of the affluent and the limited opportunities for the working class in terms of income disparity (Zucman 2019): a pithy explanation would be to say that history has come full circle.

The balance of power in Washington therefore privileges the preferences of the C-suite whose dollars leave little room for ordinary citizens in authoring legislation. The long list of enactments at odds with democratic ideals since backdoors rather than votes are used does vindicate the sort of symbiosis so common between the corporate sector and government. Think tanks, lobbying, campaign finance, and the revolving door of former executives now in office are all strategies that companies avail themselves of to exert influence over policy outcomes. In 1998 the Copyright Term Extension Act expanded exclusive rights to Disney over its intellectual property of Mickey Mouse from seventy-five to nine-five years as a barrier to competitors. In 1994 NAFTA exploited lower wages for automakers by offshoring supply chains in search of profitability. In 1999 the Gramm-Leach-Bliley Act consolidated commercial banks with stock exchanges and insurance providers under the aegis of ‘too-big-to-fail’ institutions like Citigroup and JPMorgan Chase. In 2003 the Medicare Modernization Act fattened the bottom line of pharmaceutical companies. In 2005 the Energy Policy Act extended the useful life of pipelines to buttress the fiscal health of companies like ExxonMobil and Chevron (Metcalf 2009). In 2008 the Troubled Asset Relief Program preserved the marketshare of General Motors and Chrysler via subsidies. In 2010 the Supreme Court in the Citizens United case equated political spending with the First Amendment right to free speech. In 2023 Big Tech has yet to be hemmed in by any type of federal privacy laws. Finally the National Defence Authorization Act backs the revenue stream for Lockheed, Raytheon and Boeing on an annual basis. These vignettes are but a few in a long saga of corporatocracy.

The birthplace of these shadow sovereigns can be sourced in the neoliberal doctrine midwifed by economists Friedrich Hayek and Milton Friedman for the Mont Pelerin Society in 1947. At the time laissez-faire capitalism came to be a nemesis at odds with the fiscal deficits legislated by the zeitgeist of Keynesianism meant to stimulate demand in the wake of WWII. By the 1970s with the onset of stagflation when economies were mired in contraction the marriage between government and the machinery of business ejected the failures of such statism in favour of austerity and its fiscal discipline with greater freedoms given to the private sector. What came to fruition was the Washington Consensus supplanting the Keynesian one as the welfare state receded in the face of supply-side economics that set greater store in deregulation and privatization of public goods. This crusade led by proponents for the shareholder value of financial assets set a premium on investment and trade as precursors to the emergence of modern globalization. A new skepticism for governments summarily begot a substantial degree of autonomy for companies to penetrate new markets in search of profitability from foreign consumption and international supply chains. Ultimately one of the many perquisites aside from political power for these fledgling oligopolies was their limited liability owed to the socialization of their financial risk borne by taxpayers.